{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:53:13Z","timestamp":1791273193198,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.iac.2026.06.004","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:55:43Z","timestamp":1785455743000},"page":"615-630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Using Asthma Phenotypes and Endotypes to Guide Treatment in Pediatric Asthma"],"prefix":"10.1016","volume":"46","author":[{"given":"Suzanne Y.","family":"Ngo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib2","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jaci.2021.10.001","article-title":"Advances in asthma: new understandings of asthma's natural history, risk factors, underlying mechanisms, and clinical management","volume":"148","author":"Miller","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.06.004_bib3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chest.2019.10.009","article-title":"Recent advances in severe asthma: from phenotypes to personalized medicine","volume":"157","author":"Schoettler","year":"2020","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.iac.2026.06.004_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cea.13014","article-title":"Features of asthma which provide meaningful insights for understanding the disease heterogeneity","volume":"48","author":"Deliu","year":"2018","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"10.1016\/j.iac.2026.06.004_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227091","article-title":"A modern approach to identifying and characterizing child asthma and wheeze phenotypes based on clinical data","volume":"14","author":"Brew","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.iac.2026.06.004_bib6","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.jaip.2020.02.032","article-title":"Heterogeneity of mild to moderate persistent asthma in children: confirmation by latent class analysis and association with 1-Year outcomes","volume":"8","author":"Fitzpatrick","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1183\/13993003.00284-2015","article-title":"Change in the manifestations of asthma and asthma-related traits in childhood: a latent transition analysis","volume":"47","author":"Garden","year":"2016","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.iac.2026.06.004_bib8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/thoraxjnl-2011-201064","article-title":"Sputum inflammatory phenotypes are not stable in children with asthma","volume":"67","author":"Fleming","year":"2012","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.iac.2026.06.004_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1164\/rccm.202201-0129OC","article-title":"Exacerbation profile and risk factors in a Type-2-Low enriched severe asthma cohort: a clinical trial to assess asthma exacerbation phenotypes","volume":"206","author":"McDowell","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/j.iac.2026.06.004_bib11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.iac.2026.06.004_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/cea.13790","article-title":"Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma","volume":"51","author":"Chen","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/all.13985","article-title":"Mechanisms and therapeutic strategies for non-T2 asthma","volume":"75","author":"Sze","year":"2020","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.iac.2026.06.004_bib14","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/all.13806","article-title":"Toward clinically applicable biomarkers for asthma: an EAACI position paper","volume":"74","author":"Diamant","year":"2019","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2026.06.004_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/all.12101","article-title":"Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma","volume":"68","author":"Ullmann","year":"2013","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib16","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the asthma management guidelines: a report from the national Asthma Education and Prevention Program Coordinating Committee expert Panel Working Group","volume":"146","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.iac.2026.06.004_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/pai.14044","article-title":"Exhaled nitric oxide is only an asthma-relevant biomarker among children with allergic sensitization","volume":"34","author":"Sunde","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.iac.2026.06.004_bib18","article-title":"Recent insights in the role of biomarkers in severe asthma management","volume":"9","author":"Fouka","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01046-2019","article-title":"Gina 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents","volume":"53","author":"Reddel","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-2600(20)30416-1","article-title":"Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study","volume":"9","author":"O'Byrne","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"20","key":"10.1016\/j.iac.2026.06.004_bib21","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJMoa1715274","article-title":"Inhaled combined budesonide-formoterol as needed in mild asthma","volume":"378","author":"O'Byrne","year":"2018","journal-title":"N Engl J Med"},{"issue":"10511","key":"10.1016\/j.iac.2026.06.004_bib22","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S0140-6736(25)00861-X","article-title":"Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial","volume":"406","author":"Hatter","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.anai.2016.07.035","article-title":"Pivotal efficacy trials of inhaled corticosteroids in asthma","volume":"117","author":"Covar","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.06.004_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2014.10.026","article-title":"Biomarker-based asthma phenotypes of corticosteroid response","volume":"135","author":"Cowan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.06.004_bib25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaip.2015.01.023","article-title":"Markers of differential response to inhaled corticosteroid treatment among children with mild persistent asthma","volume":"3","author":"Gerald","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2026.06.004_bib26","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/abc4ec","article-title":"Correlations between exhaled nitric oxide, rs28364072 polymorphism of FCER2 gene, asthma control, and inhaled corticosteroid responsiveness in children with asthma","volume":"15","author":"Duong-Quy","year":"2020","journal-title":"J Breath Res"},{"issue":"5","key":"10.1016\/j.iac.2026.06.004_bib27","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jaci.2018.09.034","article-title":"Integrative approach identifies corticosteroid response variant in diverse populations with asthma","volume":"143","author":"Levin","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2004.11.014","article-title":"Characterization of within-subject responses to fluticasone and montelukast in childhood asthma","volume":"115","author":"Szefler","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2008.11.016","article-title":"Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma","volume":"123","author":"Knuffman","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib30","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jaci.2016.09.028","article-title":"Individualized therapy for persistent asthma in young children","volume":"138","author":"Fitzpatrick","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1164\/rccm.200407-884OC","article-title":"Budesonide\/formoterol combination therapy as both maintenance and reliever medication in asthma","volume":"171","author":"O'Byrne","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib32","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1378\/chest.130.6.1733","article-title":"Budesonide\/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma","volume":"130","author":"Bisgaard","year":"2006","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.iac.2026.06.004_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12890-017-0401-y","article-title":"Efficacy of budesonide\/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment","volume":"17","author":"Jenkins","year":"2017","journal-title":"BMC Pulm Med"},{"issue":"11","key":"10.1016\/j.iac.2026.06.004_bib34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa1001278","article-title":"Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids","volume":"362","author":"Lemanske","year":"2010","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.iac.2026.06.004_bib35","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1905560","article-title":"Step-Up therapy in black children and adults with poorly controlled asthma","volume":"381","author":"Wechsler","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.iac.2026.06.004_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/HGWT3617","article-title":"Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data","volume":"29","author":"Cividini","year":"2025","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.iac.2026.06.004_bib37","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01100-2016","article-title":"A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma","volume":"49","author":"Hamelmann","year":"2017","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.iac.2026.06.004_bib38","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.jaip.2019.03.019","article-title":"Tiotropium is efficacious in 6- to 17-Year-Olds with asthma, independent of T2 phenotype","volume":"7","author":"Szefler","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2026.06.004_bib39","series-title":"Xolair (omalizumab)","year":"2024"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib40","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"Milgrom","year":"2001","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib41","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.iac.2026.06.004_bib42","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.iac.2026.06.004_bib43","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","article-title":"\u201cReal-life\u201d effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study","volume":"103","author":"Brusselle","year":"2009","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.iac.2026.06.004_bib44","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.jaip.2020.03.033","article-title":"Treatment benefit with omalizumab in children by indicators of asthma severity","volume":"8","author":"Szefler","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jaip.2013.01.011","article-title":"Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents","volume":"1","author":"Sorkness","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.iac.2026.06.004_bib46","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib47","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2026.06.004_bib48","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/j.jaip.2020.03.051","article-title":"Aeroallergen sensitization, serum IgE, and eosinophilia as predictors of response to omalizumab therapy during the fall season among children with persistent asthma","volume":"8","author":"Sheehan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2026.06.004_bib49","series-title":"Nucala (mepolizumab)","year":"2019"},{"issue":"1","key":"10.1016\/j.iac.2026.06.004_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13223-019-0366-x","article-title":"Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma","volume":"15","author":"Yancey","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"10351","key":"10.1016\/j.iac.2026.06.004_bib51","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.iac.2026.06.004_bib52","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.jaip.2023.07.028","article-title":"Controversies in allergy: are biologic treatment responses in severe asthma the same in adults and children?","volume":"11","author":"Gaberino","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2024.01.031","article-title":"Activated sputum eosinophils associated with exacerbations in children on mepolizumab","volume":"154","author":"Wilson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2026.06.004_bib54","series-title":"Fasenra (benralizumab)","year":"2024"},{"issue":"10056","key":"10.1016\/j.iac.2026.06.004_bib55","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.iac.2026.06.004_bib56","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.iac.2026.06.004_bib57","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.iac.2026.06.004_bib58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.iac.2026.06.004_bib59","series-title":"Dupixent (dupilumab). Package insert","year":"2024"},{"issue":"26","key":"10.1016\/j.iac.2026.06.004_bib60","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.iac.2026.06.004_bib61","first-page":"2621","article-title":"Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma","volume":"76","author":"Maspero","year":"2021","journal-title":"Liberty Asthma Quest Allergy"},{"issue":"24","key":"10.1016\/j.iac.2026.06.004_bib62","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.iac.2026.06.004_bib63","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1111\/all.15743","article-title":"Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma","volume":"78","author":"Papadopoulos","year":"2023","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2026.06.004_bib64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2023.09.044","article-title":"Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma","volume":"154","author":"Bacharier","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2026.06.004_bib65","series-title":"Tezspire (tezepelumab-ekko)","year":"2023"},{"issue":"1","key":"10.1016\/j.iac.2026.06.004_bib66","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","article-title":"NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"issue":"19","key":"10.1016\/j.iac.2026.06.004_bib67","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.iac.2026.06.004_bib68","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1814917","article-title":"Mometasone or tiotropium in mild asthma with a low sputum eosinophil level","volume":"380","author":"Lazarus","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib69","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.chest.2022.02.025","article-title":"Azithromycin for poorly controlled asthma in children: a randomized controlled trial","volume":"161","author":"Ghimire","year":"2022","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.iac.2026.06.004_bib70","first-page":"CD002997","article-title":"Macrolides for chronic asthma","author":"Kew","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.iac.2026.06.004_bib71","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.jaip.2021.04.033","article-title":"Management strategies to reduce exacerbations in non-T2 asthma","volume":"9","author":"Murphy","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib72","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.jaci.2011.03.036","article-title":"Obesity and asthma: an association modified by age of asthma onset","volume":"127","author":"Holguin","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.06.004_bib73","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaci.2010.12.010","article-title":"Decreased response to inhaled steroids in overweight and obese asthmatic children","volume":"127","author":"Forno","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.06.004_bib74","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaip.2017.07.010","article-title":"Overweight, obesity, and lung function in children and Adults-A meta-analysis","volume":"6","author":"Forno","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.iac.2026.06.004_bib75","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.3390\/biomedicines11102797","article-title":"Obesity-Associated Non-T2 mechanisms in Obese asthmatic individuals","volume":"11","author":"Shailesh","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.iac.2026.06.004_bib76","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1164\/rccm.202406-1166SO","article-title":"Obesity-related asthma: a pathobiology-based overview of existing and emerging treatment approaches","volume":"210","author":"Althoff","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.iac.2026.06.004_bib77","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1016\/j.jaip.2025.07.041","article-title":"Effects of obesity on response to asthma biologic treatment: longitudinal data from the United Kingdom severe asthma registry","volume":"13","author":"Gonem","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157158","article-title":"A multifactorial weight reduction programme for children with overweight and asthma: a randomized controlled trial","volume":"11","author":"Willeboordse","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.iac.2026.06.004_bib79","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11882-024-01153-x","article-title":"Weighted breaths: exploring biologic and non-biologic therapies for Co-Existing asthma and obesity","volume":"24","author":"Pilkington","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"issue":"6","key":"10.1016\/j.iac.2026.06.004_bib80","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-4496","article-title":"Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis","volume":"137","author":"Kaiser","year":"2016","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.iac.2026.06.004_bib81","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1111\/j.1398-9995.2009.02134.x","article-title":"Regular vs prn nebulized treatment in wheeze preschool children","volume":"64","author":"Papi","year":"2009","journal-title":"Allergy"},{"issue":"21","key":"10.1016\/j.iac.2026.06.004_bib82","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1056\/NEJMoa1104647","article-title":"Daily or intermittent budesonide in preschool children with recurrent wheezing","volume":"365","author":"Zeiger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.iac.2026.06.004_bib83","article-title":"Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children","volume":"2015","author":"Brodlie","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.1016\/j.iac.2026.06.004_bib84","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1001\/jama.2015.13896","article-title":"Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial","volume":"314","author":"Bacharier","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.iac.2026.06.004_bib85","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-2600(15)00500-7","article-title":"Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Stokholm","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.iac.2026.06.004_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182411","article-title":"Treatment of preschool children presenting to the emergency department with wheeze with azithromycin: a placebo-controlled randomized trial","volume":"12","author":"Mandhane","year":"2017","journal-title":"PLoS One"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:25:45Z","timestamp":1791271545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856126000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0889856126000597"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2026.06.004","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using Asthma Phenotypes and Endotypes to Guide Treatment in Pediatric Asthma","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2026.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}